. 2021 Jun 18;5(10):1632–1648. doi: 10.1002/hep4.1708

TABLE 1.

Selected Prospective Studies Assessing NA Discontinuation in HBeAg‐Negative Patients

Study	Region	Design	HBeAg‐Negative Patients With NA Discontinued (n)	Endpoint(s)	NA	Mean NA Treatment Duration, Range (Months)	Mean Post‐NA Follow‐up, Range (Months)	HBV‐DNA Relapses (%)	HBsAg Loss (%)	No Retreatment (%)
Liu et al.⁽ ⁴¹ ⁾	China	Prospective	61	HBV‐DNA relapse; HBsAg loss	LMV +/− PEG‐IFN	30 (24‐66)	22 (1‐84)	56	10	N/A
Ha et al.⁽ ⁴⁵ ⁾	China	Prospective	145	HBV‐DNA relapse; HBsAg loss	ADV +/− IFN‐α	26 (24‐66)^*	16 (1‐88)^*	65.5	8.3	N/A
Seto et al.⁽ ⁵⁹ ⁾	China	Prospective	184	HBV‐DNA relapse; HBsAg loss; immune control	ETV	≥24	12	91.4	0	8.4^†
Karakaya et al.⁽ ⁶⁰ ⁾	Turkey	Prospective	23	HBV‐DNA relapse; HBsAg loss	LMV	>60	12‐60	45	9	9
Cao et al.⁽ ⁶¹ ⁾	China	Prospective	22	HBV‐DNA relapse; HBsAg loss	ETV, ADV, LdT, LMV	47 (29‐77)	N/A	53	N/A	N/A
Berg et al.⁽ ⁶² ⁾	Germany	Prospective, randomized	21	HBsAg loss; retreatment	TDF	33	36	100	19	43
Rivino et al.⁽ ²⁶ ⁾	Great Britain	Prospective	21/27	HBV‐DNA relapse	TDF, LMV	≥24/≥24	12	N/A	0	19/51
Papatheodoridis et al.⁽ ⁶³ ⁾	Greece	Prospective	57	HBV‐DNA relapse; retreatment	ETV, TDF	>48	18	72	25	74^†
Liem et al.⁽ ⁶⁸ ⁾	Asian patients (98%)	Prospective, randomized	27	HBV DNA < 2,000 IU/mL; HBsAg loss	TDF, ETV	91	18	100	1 (2.2)	17 (38%)
van Bömmel et al.⁽ ⁷⁰ ⁾	European patients	Prospective, randomized	79	HBsAg loss	TDF, ETV, LdT, LMV	>48	24	100	8 (10.3)	53 (67.9%)

Any ALT increase.

^{^†}

Any HBV‐DNA increase.

Abbreviations: ADV, adefovir dipivoxil; IFN, interferon; N/A, not applicable; PEG‐IFN, pegylated interferon.